Macromolecular Bioscience 2016-01-01

N-(2-Hydroxypropyl)methacrylamide Copolymer-Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia.

Rui Zhang, Jiyuan Yang, Yan Zhou, Paul J Shami, Jindřich Kopeček

Index: Macromol. Biosci. 16 , 121-8, (2016)

Full Text: HTML

Abstract

There is a need for new treatment strategies of acute myeloid leukemia (AML). In this study, four different drugs, including cytarabine, daunorubicin, GDC-0980, and JS-K, were investigated in vitro for the two-drug combinations treatment of AML. The results revealed that cytarabine and GDC-0980 had the strongest synergism. In addition, cell cycle analysis was conducted to investigate the effect of the different combinations on cell division. For future in vivo application, N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-cytarabine and GDC-0980 conjugates were synthesized, respectively. In vitro studies demonstrated that both conjugates had potent cytotoxicity and their combination also showed strong synergy, suggesting a potential chemotherapeutic strategy for future AML treatment. © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.


Related Compounds

Related Articles:

Nitric oxide-releasing prodrug triggers cancer cell death through deregulation of cellular redox balance.

2013-01-01

[Redox Biol. 1 , 115-24, (2013)]

JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells.

2012-01-01

[BMC Cancer 12 , 130, (2012)]

More Articles...